[go: up one dir, main page]

ECSP18014922A - Composiciones de insulina de rápida acción - Google Patents

Composiciones de insulina de rápida acción

Info

Publication number
ECSP18014922A
ECSP18014922A ECIEPI201814922A ECPI201814922A ECSP18014922A EC SP18014922 A ECSP18014922 A EC SP18014922A EC IEPI201814922 A ECIEPI201814922 A EC IEPI201814922A EC PI201814922 A ECPI201814922 A EC PI201814922A EC SP18014922 A ECSP18014922 A EC SP18014922A
Authority
EC
Ecuador
Prior art keywords
fast
acting insulin
insulin compositions
insulin analog
insulin
Prior art date
Application number
ECIEPI201814922A
Other languages
English (en)
Inventor
Virender Kumar Sarin
Ranajoy Majumdar
Chad D Paavola
Michael Patrick Akers
Michael Edward Christe
Nanette Elizabeth Schulte
Thomas Andrew Hardy
Chi A Nguyen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP18014922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP18014922A publication Critical patent/ECSP18014922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de insulina humana o análogo de insulina que incluye citrato, treprostinilo y agentes estabilizantes, que tiene acción farmacocinética y farmacodinámica más rápida que las formulaciones comerciales de productos análogos de insulina existentes y que es estable para uso comercial.
ECIEPI201814922A 2015-08-27 2018-02-27 Composiciones de insulina de rápida acción ECSP18014922A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
ECSP18014922A true ECSP18014922A (es) 2018-04-30

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201814922A ECSP18014922A (es) 2015-08-27 2018-02-27 Composiciones de insulina de rápida acción

Country Status (39)

Country Link
US (3) US9901623B2 (es)
EP (2) EP3340966B1 (es)
JP (2) JP6359780B2 (es)
KR (1) KR102018998B1 (es)
CN (1) CN107920992B (es)
AR (1) AR105712A1 (es)
AU (1) AU2016310475B2 (es)
BR (1) BR112018001755A2 (es)
CA (1) CA2994427C (es)
CL (1) CL2018000503A1 (es)
CO (1) CO2018002026A2 (es)
CR (1) CR20180118A (es)
DK (1) DK3340966T3 (es)
DO (1) DOP2018000059A (es)
EA (1) EA033396B1 (es)
EC (1) ECSP18014922A (es)
ES (1) ES2928664T3 (es)
FI (1) FI3340966T3 (es)
HR (1) HRP20221367T1 (es)
HU (1) HUE060626T2 (es)
IL (1) IL256939B (es)
JO (1) JO3749B1 (es)
LT (1) LT3340966T (es)
MA (1) MA42701B1 (es)
MD (1) MD3340966T2 (es)
MX (1) MX379267B (es)
MY (1) MY195781A (es)
NZ (1) NZ739338A (es)
PE (1) PE20180782A1 (es)
PH (1) PH12018500422B1 (es)
PL (1) PL3340966T3 (es)
PT (1) PT3340966T (es)
RS (1) RS63731B1 (es)
SV (1) SV2018005643A (es)
TN (1) TN2018000056A1 (es)
TW (1) TWI614025B (es)
UA (1) UA120142C2 (es)
WO (1) WO2017034956A1 (es)
ZA (1) ZA201800511B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014076423A1 (fr) 2012-11-13 2014-05-22 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3518893A1 (en) 2016-09-29 2019-08-07 Arecor Limited Novel formulations
MX2019014195A (es) * 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
WO2019050749A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
WO2019193351A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US12357562B2 (en) 2018-04-04 2025-07-15 Arecor Limited Injection pen system for the delivery of an insulin compound
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
EA202190552A1 (ru) * 2018-09-18 2021-06-18 Эли Лилли Энд Компани Эрбуминовая соль трепростинила
JP7518149B2 (ja) * 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
FI884914A0 (fi) 1987-02-25 1988-10-24 Novo Industri As Nya insulinderivat.
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
WO2001035943A2 (en) 1999-11-15 2001-05-25 Gangal Hanamaraddi T Dextrose and insulin fluid formulation for intravenous infusion
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE60335797D1 (de) 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
GB2419529B (en) * 2003-07-17 2008-01-09 Cotherix Inc Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
ES2347254T3 (es) * 2003-12-16 2010-10-27 United Therapeutics Corporation Utilizacion de treprostinil para el tratamiento de las lesiones isquemicas.
ES2328048T3 (es) 2004-03-12 2009-11-06 Biodel, Inc. Composiciones de insulina con absorcion mejorada.
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR101186029B1 (ko) 2004-04-12 2012-09-27 유나이티드 쎄러퓨틱스 코포레이션 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도
EP1846446B1 (en) * 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007038670A2 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2190433A2 (en) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
DK2328636T3 (da) 2008-08-28 2013-09-02 Medingo Ltd Anordning til forbedret subkutan insulinabsorption
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
RU2533217C3 (ru) 2009-06-26 2020-12-21 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
EP2651446A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CN103889443A (zh) 2011-06-17 2014-06-25 哈洛齐梅公司 使用透明质酸降解酶的持续皮下胰岛素输注法
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
JP6944780B2 (ja) 2014-01-13 2021-10-06 サーマリン インコーポレイテッド 速効型インスリン製剤及び医薬送達システム
WO2015120457A1 (en) * 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
WO2017015760A1 (en) 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
KR102018998B1 (ko) 2019-09-05
UA120142C2 (uk) 2019-10-10
PE20180782A1 (es) 2018-05-07
PT3340966T (pt) 2022-12-05
RS63731B1 (sr) 2022-12-30
KR20180033276A (ko) 2018-04-02
HRP20221367T1 (hr) 2023-01-06
SV2018005643A (es) 2018-10-09
MY195781A (en) 2023-02-13
US9901623B2 (en) 2018-02-27
CN107920992B (zh) 2021-06-18
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
CA2994427C (en) 2019-07-09
EP4169505A1 (en) 2023-04-26
JP2018507869A (ja) 2018-03-22
JO3749B1 (ar) 2021-01-31
JP2018172404A (ja) 2018-11-08
MA42701A (fr) 2018-07-04
US20210169988A1 (en) 2021-06-10
CR20180118A (es) 2018-03-20
TW201717997A (zh) 2017-06-01
BR112018001755A2 (pt) 2018-09-18
DK3340966T3 (da) 2022-10-24
ES2928664T3 (es) 2022-11-21
PH12018500422A1 (en) 2018-08-29
EP3340966B1 (en) 2022-10-12
TWI614025B (zh) 2018-02-11
IL256939A (en) 2018-03-29
CL2018000503A1 (es) 2018-08-03
WO2017034956A1 (en) 2017-03-02
JP6359780B2 (ja) 2018-07-18
EP3340966A1 (en) 2018-07-04
CA2994427A1 (en) 2017-03-02
EA201890343A1 (ru) 2018-07-31
HUE060626T2 (hu) 2023-03-28
ZA201800511B (en) 2019-07-31
IL256939B (en) 2019-10-31
EA033396B1 (ru) 2019-10-31
AR105712A1 (es) 2017-11-01
AU2016310475B2 (en) 2018-10-18
MD3340966T2 (ro) 2023-04-30
US20180140676A1 (en) 2018-05-24
LT3340966T (lt) 2022-11-25
MX2018002482A (es) 2018-06-15
JP6935364B2 (ja) 2021-09-15
CN107920992A (zh) 2018-04-17
DOP2018000059A (es) 2018-04-15
US20170056478A1 (en) 2017-03-02
FI3340966T3 (fi) 2023-01-13
PL3340966T3 (pl) 2023-01-30
AU2016310475A1 (en) 2018-02-15
MX379267B (es) 2025-03-11
US10925931B2 (en) 2021-02-23
CO2018002026A2 (es) 2018-05-21
PH12018500422B1 (en) 2022-04-01
MA42701B1 (fr) 2023-01-31

Similar Documents

Publication Publication Date Title
ECSP18014922A (es) Composiciones de insulina de rápida acción
MX367521B (es) Composiciones de insulina de rápida acción.
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
DOP2016000253A (es) Nuevos compuestos
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
MX372607B (es) Sal de succinato de citisina y uso de la misma
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
ECSP19085451A (es) Composiciones de insulina de rápida acción
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
BR112018001836A2 (pt) preparação contendo octocrileno estável ao odor
MA39115A2 (fr) Régulateurs de nrf2